Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta
- PMID: 24334069
- DOI: 10.1016/j.neuropharm.2013.12.007
Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta
Abstract
Endocannabinoids (eCBs) modulate synaptic transmission in the brain, but little is known of their regulatory role in nigral dopaminergic neurons, and whether transmission to these neurons is tonically inhibited by eCBs as seen in some other brain regions. Using whole-cell recording in midbrain slices, we observed potentiation of evoked IPSCs (eIPSCs) in these neurons after blocking CB1 receptors with rimonabant or LY-320,135, indicating the presence of an eCB tone reducing inhibitory synaptic transmission. Increased postsynaptic calcium buffering and block of mGluR1 or postsynaptic G-protein coupled receptors prevented this potentiation. Increasing spillover of endogenous glutamate by inhibiting uptake attenuated eIPSC amplitude, while enhancing the potentiation by rimonabant. Group I mGluR activation transiently inhibited eIPSCs, which could be prevented by GDP-β-S, increased calcium buffering or rimonabant. We explored the possibility that the dopamine-derived eCB N-arachidonoyl dopamine (NADA) is involved. The eCB tone was abolished by preventing dopamine synthesis, and enhanced by l-DOPA. It was not detected in adjacent non-dopaminergic neurons. Preventing 2-AG synthesis did not affect the tone, while inhibition of NADA production abolished it. Quantification of ventral midbrain NADA suggested a basal level that increased following prolonged depolarization or mGluR activation. Since block of the tone was not always accompanied by attenuation of depolarization-induced suppression of inhibition (DSI) and vice versa, our results indicate DSI and the eCB tone are mediated by distinct eCBs. This study provides evidence that dopamine modulates the activity of SNc neurons not only by conventional dopamine receptors, but also by CB1 receptors, potentially via NADA.
Keywords: Cannabinoids; Dopaminergic; Electrophysiology; Parkinson's disease; Synaptic transmission.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Excitatory drive from the Subthalamic nucleus attenuates GABAergic transmission in the Substantia Nigra pars compacta via endocannabinoids.Eur J Pharmacol. 2015 Nov 15;767:144-51. doi: 10.1016/j.ejphar.2015.09.050. Epub 2015 Oct 16. Eur J Pharmacol. 2015. PMID: 26472124
-
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.Neuropsychopharmacology. 2007 Feb;32(2):298-308. doi: 10.1038/sj.npp.1301118. Epub 2006 Jun 7. Neuropsychopharmacology. 2007. PMID: 16760924
-
Endocannabinoid- and mGluR5-dependent short-term synaptic depression in an isolated neuron/bouton preparation from the hippocampal CA1 region.J Neurophysiol. 2008 Aug;100(2):1041-52. doi: 10.1152/jn.90226.2008. Epub 2008 May 21. J Neurophysiol. 2008. PMID: 18497350 Free PMC article.
-
The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area.Life Sci. 1992;51(10):711-8. doi: 10.1016/0024-3205(92)90479-9. Life Sci. 1992. PMID: 1355254 Review.
-
The endocannabinoid system in Parkinson's disease.Curr Pharm Des. 2008;14(23):2337-47. doi: 10.2174/138161208785740072. Curr Pharm Des. 2008. PMID: 18781984 Review.
Cited by
-
Adolescent Exposure to WIN 55212-2 Render the Nigrostriatal Dopaminergic Pathway Activated During Adulthood.Int J Neuropsychopharmacol. 2020 Dec 3;23(9):626-637. doi: 10.1093/ijnp/pyaa053. Int J Neuropsychopharmacol. 2020. PMID: 32710782 Free PMC article.
-
Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.Br J Pharmacol. 2016 Jan;173(1):115-27. doi: 10.1111/bph.13341. Epub 2015 Nov 17. Br J Pharmacol. 2016. PMID: 26398720 Free PMC article.
-
N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities.Cannabis Cannabinoid Res. 2017 Jul 1;2(1):183-196. doi: 10.1089/can.2017.0015. eCollection 2017. Cannabis Cannabinoid Res. 2017. PMID: 29082315 Free PMC article. Review.
-
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.Mol Neurodegener. 2015 Apr 8;10:17. doi: 10.1186/s13024-015-0012-0. Mol Neurodegener. 2015. PMID: 25888232 Free PMC article. Review.
-
The Role of Lipids in Parkinson's Disease.Cells. 2019 Jan 7;8(1):27. doi: 10.3390/cells8010027. Cells. 2019. PMID: 30621069 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous